KRAS and non-small cell lung carcinoma: NGS testing on 166 ROS1+ NSCLC without associated clinical information identified 1 patient with ROS1+ NSCLC with a concurrent EGFR L858R mutation and 3 patients with ROS1+ NSCLC and a KRAS activating mutation (Q61R, G12R, G12C)7.